Screening studies demonstrated it was possible to disrupt the Hsp90/Aha1 complex via small molecules, which may provide an opportunity to treat disease states such as neurodegeneration and/or cystic fibrosis. This evidence concerns the gene HSP90AB1 and cystic fibrosis.